Cell-free molecular testing will make it easier to address important health problems worldwide and will lead to significant advances in personalized medicine for improved patient care. Trovagene anticipates that cf-NA analysis will have great utility in monitoring oncogene mutations following treatment, for detection of minimal residual disease, and for early detection of recurrence.
Assays planned to be available through Trovagene's CLIA laboratory include:
• KRAS mutation detection and monitoring: These mutations are frequently found in pancreatic, colorectal, lung, and ovarian cancers, among others. This test, which will monitor KRAS mutations in TrNA, is planned for launch in 2013.
• BRAF mutation detection and monitoring: Found frequently in skin (melanoma), thyroid, colon and other cancers.
• PIK3CA mutation detection and monitoring: These mutations occur frequently in cancers of the breast, colon, and endometrium.